Administrative Core
Administrative Core
批准号:
7694038
负责人:
HARRIET L ROBINSON
金额:
$30.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-01 至 2012-08-31
关键词:
AccountingAcquired Immunodeficiency SyndromeAdjuvantAfricaAnnual ReportsAsiaBiological AssayBudgetsC-PeptideCSF2 geneCause of DeathClinical TrialsConsultationsCountryDNADNA/MVA vaccineDataEnsureGoalsGranulocyte-Macrophage Colony-Stimulating FactorHIV-1Immune responseIndiaInfectionIntellectual PropertyLeadLeadershipLegal patentMediationModelingMucosal Immune ResponsesNumbersPhasePublicationsPublishingQuality ControlRecordsResourcesSouth AfricaSouthern AfricaT-LymphocyteTestingUnited States National Institutes of HealthVaccinesVirus-like particleconceptdata managementdoxorubicin/mitomycin/vinblastine protocolexperienceimprovedpreclinical studyprogramsquality assuranceresponsevaccine developmentvector
中文摘要
由HIV-1引起的获得性免疫缺陷综合征(AIDS)是人类死亡的主要原因
英文摘要
The acquired immunodeficiency syndrome (AIDS) caused by HIV-1 is the leading cause of death in
Africa and the fourth leading cause of death worldwide. This IPCAVD is developing HIV/AIDS vaccines that
use DNA for priming and MVA for boosting (DNA/MVA vaccine) as well as a simpler an ultimately easier to
deploy form of these vaccines, the use of MVA for both priming and boosting (MVA/MVA vaccine). Both the
DNA and MVA vaccines use single vectors to express virus like particles (VLP). This IPCAVD seeks to build
GM-CSF, an adjuvant, into these products for expression in cis. In preclinical studies, co-expression of GMCSF
has substantially enhanced protection. A central hypothesis for the IPCAVD is that GM-CSF improves
protection by enhancing the mucosal presence of elicited T cell and Ab responses. Clade C HIV-1 which is
endemic in southern Africa and parts of Asia accounts for about one half of the infections worldwide and
>90% of the cases in India, a country with a rapidly spreading infection that has surpassed South Africa in its
total number of cases. The vaccine development effort of this IPCAVD is focused on developing a clade C
vaccine for India.
This administrative core has five specific aims:
¿ Provide overall co-ordination for the Program
¿ Provide data management and statistical support
¿ Provide logistical support for intellectual property filings and negotiations
¿ Assist with publications
¿ Maintain budgets and fiscal oversight
Dr. Harriet Robinson, the Program Director, will lead the Administrative core. She has demonstrated
experience in leading IPCAVD programs and moving concepts from the bench to early phase clinical trials
through the HVTN.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine
-
批准号:8709988
-
项目类别:
-
资助金额:$28.96万
-
财政年份:2013
-
负责人:HARRIET L ROBINSON
-
依托单位:
Project 1: Immunogens and Manufacturing
-
批准号:8478317
-
项目类别:
-
资助金额:$185.9万
-
财政年份:2012
-
负责人:HARRIET L ROBINSON
-
依托单位:
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES
-
批准号:7715685
-
项目类别:
-
资助金额:$8.16万
-
财政年份:2008
-
负责人:HARRIET L ROBINSON
-
依托单位:
Clinical Trials and Ancillary Assays
-
批准号:7679565
-
项目类别:
-
资助金额:$44.79万
-
财政年份:2008
-
负责人:HARRIET L ROBINSON
-
依托单位:
Administrative Support
-
批准号:7280624
-
项目类别:
-
资助金额:$34.21万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines
-
批准号:7497586
-
项目类别:
-
资助金额:$347.87万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines
-
批准号:7938758
-
项目类别:
-
资助金额:$488.51万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines
-
批准号:7269092
-
项目类别:
-
资助金额:$291.51万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
Clinical Trials and Ancillary Assays
-
批准号:7280623
-
项目类别:
-
资助金额:$43.72万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES
-
批准号:7562528
-
项目类别:
-
资助金额:$10.47万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines
-
批准号:7679567
-
项目类别:
-
资助金额:$473.63万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines
-
批准号:8132550
-
项目类别:
-
资助金额:$435.23万
-
财政年份:2007
-
负责人:HARRIET L ROBINSON
-
依托单位:
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES
-
批准号:7349168
-
项目类别:
-
资助金额:$10.74万
-
财政年份:2006
-
负责人:HARRIET L ROBINSON
-
依托单位:
PROJECT 1: DNA AND MVA IMMUNOGENS
-
批准号:7349169
-
项目类别:
-
资助金额:$10.74万
-
财政年份:2006
-
负责人:HARRIET L ROBINSON
-
依托单位:
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES
-
批准号:7349125
-
项目类别:
-
资助金额:$10.74万
-
财政年份:2006
-
负责人:HARRIET L ROBINSON
-
依托单位:
PROJECT 1: DNA IMMUNOGENS AND PRECLINICAL TRIALS
-
批准号:7165903
-
项目类别:
-
资助金额:$9.64万
-
财政年份:2005
-
负责人:HARRIET L ROBINSON
-
依托单位:
PROJECT 1: DNA AND MVA IMMUNOGENS
-
批准号:7165900
-
项目类别:
-
资助金额:$9.64万
-
财政年份:2005
-
负责人:HARRIET L ROBINSON
-
依托单位:
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES
-
批准号:7165899
-
项目类别:
-
资助金额:$9.64万
-
财政年份:2005
-
负责人:HARRIET L ROBINSON
-
依托单位:
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES
-
批准号:7165848
-
项目类别:
-
资助金额:$9.64万
-
财政年份:2005
-
负责人:HARRIET L ROBINSON
-
依托单位:
BASIC PRINCIPALS OF DNA-BASED IMMUNIZATIONS
-
批准号:6970936
-
项目类别:
-
资助金额:$3.58万
-
财政年份:2004
-
负责人:HARRIET L ROBINSON
-
依托单位:
海外基金